Atezolizumab is a medication used in this trial to help the body’s immune system attack cancer cells. It works by blocking a protein that stops the immune system from working properly, allowing it to better target and destroy cancer cells.

Bevacizumab is another medication used in combination with atezolizumab. It works by blocking the growth of new blood vessels that tumors need to grow and spread. This helps to slow down or stop the growth of cancer.

Transarterial Chemoembolization (TACE) is a procedure used in this trial as a comparison to the medications. It involves delivering chemotherapy directly to the liver tumor through the blood vessels, while also blocking the blood supply to the tumor. This helps to shrink the tumor and limit its growth.

Intermediate-stage Hepatocellular Carcinoma – This is a type of liver cancer that occurs when malignant cells form in the tissues of the liver. It is considered intermediate-stage when the cancer has not spread to distant parts of the body but may have grown into nearby blood vessels or lymph nodes. Patients at this stage often have multiple tumors in the liver, and the liver function is usually still adequate. The disease progresses as the tumors grow larger or increase in number, potentially affecting liver function over time. Symptoms may include abdominal pain, weight loss, and jaundice, although some individuals may not experience noticeable symptoms initially. The progression can vary, and monitoring is essential to manage the condition effectively.